Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)

NCT00288704 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

104

Enrollment

INDUSTRY

Sponsor class

Conditions

Familial Cold Autoinflammatory Syndrome (FCAS)
Familial Cold Urticaria
Muckle-Wells Syndrome (MWS)
Genetic Diseases, Inborn

Interventions

DRUG: rilonacept 160 mg
DRUG: Placebo
DRUG: rilonacept 160 mg

Sponsor

Regeneron Pharmaceuticals